Market Insights
The Arthritis Foundation defines psoriatic arthritis as an autoimmune inflammatory disease that primarily affects the skin. The majority of psoriasis patients develop psoriatic arthritis in the later stages of the disease. Psoriatic arthritis affects men and women equally, with a global prevalence rate of 6 per 100,000 people. It is a diverse disease with five subtypes: symmetric psoriatic arthritis, asymmetric psoriatic arthritis, distal psoriatic arthritis, spondylitis, and arthritis mutilans. The factors driving the psoriatic arthritis treatment market are rising public health awareness regarding skin diseases, early disease diagnosis, and the recent development of interleukin-17 inhibitors. The occurrence is highest in the Caucasian populations of North America and Europe, followed by Asia and the Pacific.
According to the International Federation of Psoriasis Associations (IFPA) 2016 statistics, around 125 million people throughout the globe are suffering from psoriatic arthritis. The diagnosis of psoriatic arthritis is complex due to the presence of symptoms in patients such as tendinitis, inflammatory spinal pain, or dactylitis, which are most often misunderstood as arthritis. Currently, the drugs prescribed for psoriatic arthritis are based on the severity of the disease, such as mild, moderate, or severe psoriatic arthritis. The development of Interleukin-17 inhibitors such as secukinumab, ixekizumab, and brodalumab has improved drug safety and efficacy for the treatment of psoriatic arthritis. ABT-494 (Abbvie, Inc.), Aprelimast (Celgene Corporation), and Certolizumab Pegol (UCB BIOSCIENCES GmbH) are being developed as targeted therapies and are set to launch during the forecast period from 2018 to 2026 and capitalize on the psoriatic arthritis treatment market.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
The psoriatic arthritis treatment market is segmented on the following basis:
Mechanism of Action
- TNF Inhibitors
- PDE4 Inhibitors
- Interleukin Blockers
- Others
Geography
- North America
- Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Key players identified for the psoriatic arthritis treatment market include:
Abbvie, Inc.; Amgen, Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; F. Hoffmann-La-Roche AG; Janssen Global Services; Merck & Co.; Novartis AG; Valeant Pharmaceuticals International, Inc.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
This report offers the following:
- For the purposes of this report, 2017 is considered the base year, with the forecast period extending from 2018 to 2026. The market size and compound annual growth rate are given in the market assessment studies.
- To understand the business strategy of the key players in the psoriatic arthritis market, an appealing investment proposition is provided for the mechanism of action and geography segment.
- Emerging biosimilars, which are an alternative to the biologic drugs employed for the treatment of psoriatic arthritis, have created a competitive environment among the key players.
- The company profiles segment provides the diverse drugs available for the treatment of psoriatic arthritis in the product portfolio segment.
- The key developments sections provide detailed information on the competitors’ most recent growth strategies.
